PMID- 29156727
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 49
DP  - 2017 Oct 17
TI  - Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 
      and disease.
PG  - 85392-85400
LID - 10.18632/oncotarget.19907 [doi]
AB  - Interferon regulator factor 4 (IRF4) is characterized to be a member of 
      interferon regulatory family, which is predominantly expressed in bone marrow 
      plasma cells of patients with multiple myeloma (MM). Recent studies indicated 
      IRF4 is critical for T-help cells (Th17) differentiation and interleukin-17 
      (IL-17) secretion. Here, a total of 58 MM patients were enrolled in this study, 
      the proportions of Th17 cells and T regulatory (Treg) cells in peripheral blood 
      mononuclear cells (PBMCs) were determined by flow cytometric analysis. 
      Immunohistochemistry was employed to detect the IRF4 expression in bone marrow. 
      Herein, we observed a significant increase of IRF4 in bone marrow accompanied 
      with a notable up-regulation of Th17 cells in PBMC within MM patients compared 
      with healthy donors. Furthermore, the proportions of Th17 cells and serum IL-17 
      levels were higher in patients with stage III than stage I & II MM patients, and 
      those parameters were positively correlated with the expression of IRF4 in these 
      cases. These results for the first time indicate that a crosstalk between IRF4 
      and Th17 cells is associated with MM prognosis, and IRF4 may be served an 
      important target for MM immunotherapy.
FAU - Bai, Hua
AU  - Bai H
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing, China.
FAU - Wu, Shuang
AU  - Wu S
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing, China.
FAU - Wang, Rong
AU  - Wang R
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing, China.
FAU - Xu, Ji
AU  - Xu J
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing, China.
FAU - Chen, Lijuan
AU  - Chen L
AD  - Department of Hematology, First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20170803
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5689617
OTO - NOTNLM
OT  - T-help cells
OT  - interferon regulator factor 4
OT  - interleukin-17
OT  - multiple myeloma
COIS- CONFLICTS OF INTEREST The authors have declared no conflicts of interest.
EDAT- 2017/11/22 06:00
MHDA- 2017/11/22 06:01
PMCR- 2017/10/17
CRDT- 2017/11/22 06:00
PHST- 2017/03/29 00:00 [received]
PHST- 2017/07/12 00:00 [accepted]
PHST- 2017/11/22 06:00 [entrez]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2017/11/22 06:01 [medline]
PHST- 2017/10/17 00:00 [pmc-release]
AID - 19907 [pii]
AID - 10.18632/oncotarget.19907 [doi]
PST - epublish
SO  - Oncotarget. 2017 Aug 3;8(49):85392-85400. doi: 10.18632/oncotarget.19907. 
      eCollection 2017 Oct 17.